Common Side Effects of Terlivaz
Terlivaz (terlipressin), approved for adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function, causes side effects in most patients due to its vasoconstrictor action. The most frequent, affecting over 10% of users in clinical trials, include:
- Abdominal pain (reported in 20-30% of patients)
- Nausea (15-20%)
- Respiratory failure (12-15%)
- Musculoskeletal pain (10-15%)
These often resolve after stopping treatment.[1][2]
Serious Side Effects and Risks
Terlivaz carries a boxed warning for serious respiratory complications. Key risks include:
- Respiratory failure: Occurs in 12% of patients; monitor breathing closely, especially in those with preexisting lung issues.
- Ischemic events: Chest pain (9%), intestinal ischemia (3-7%), and limb ischemia (2-3%) from reduced blood flow.
- Hyponatremia: Low sodium levels (up to 10%), worsening HRS symptoms.
- Infusion site reactions: Necrosis or discoloration (3-5%).
Discontinue if respiratory distress, ischemia, or bacterial infections develop. Contraindicated in patients with severe asthma, acute coronary syndrome, or uncontrolled hypertension.[1][3]
How Side Effects Compare to Alternatives
Compared to supportive care like albumin plus vasoconstrictors (e.g., norepinephrine), Terlivaz shows higher respiratory risks but better HRS reversal rates (36-40% vs. 15-25%). Midodrine/octreotide combos have fewer ischemic events but lower efficacy.[2][4]
Monitoring and Patient Concerns
Infuse continuously in a hospital; vital signs checked every 2 hours initially. Patients with ascites or liver failure report pain and nausea most. Pregnancy category not established—avoid unless benefits outweigh risks. Overdose causes hypertension and bradycardia; treat supportively.[1][3]
Clinical Trial Data on Side Effects
In the CONFIRM trial (n=300), 19% discontinued due to adverse events vs. 13% on placebo. Fatal respiratory failure: 12% Terlivaz vs. 6% placebo. Long-term data limited to 14 days max dosing.[2]
[1]: Terlivaz Prescribing Information (FDA)
[2]: CONFIRM Trial (NEJM, 2022)
[3]: Drugs.com - Terlivaz Side Effects
[4]: AASLD HRS Guidelines (2021)